SCHEMBL5040915

SCHEMBL5040915

CO[C@H](C(=O)NCc1ccc(C#N)cc1)c1ccc(N(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.53
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
ALDH1A1 P00352 5/20 0.43
MAPT P10636 2/20 0.43
GAA P10253 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MCL1 Q07820 1/20 0.43
EPHX2 P34913 1/20 0.42
LMNA P02545 1/20 0.42
CSF1R P07333 1/20 0.42
USP2 O75604 1/20 0.42
RECQL P46063 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HTT P42858 2/20 0.41
KDM4E B2RXH2 1/20 0.41
CACNA1G O43497 1/20 0.41
CACNA1H O95180 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5040908 1.00 PKM (0.53) PKMSLC1A3SLC1A2ALDH1A1MAPT
SCHEMBL5037792 0.87 PKM (0.56) PKMSLC1A3SLC1A2ALDH1A1EPHX2
SCHEMBL5037796 0.87 PKM (0.56) PKMSLC1A3SLC1A2ALDH1A1EPHX2
SCHEMBL5041218 0.85 PKM (0.72) PKMSLC1A3SLC1A2ALDH1A1GAA
SCHEMBL5040508 0.85 PKM (0.72) PKMSLC1A3SLC1A2ALDH1A1GAA
SCHEMBL5040509 0.85 PKM (0.72) PKMSLC1A3SLC1A2ALDH1A1GAA
SCHEMBL5047139 0.84 PKM (0.62) PKMSLC1A3SLC1A2ALDH1A1MEN1
SCHEMBL5038062 0.84 PKM (0.53) PKMSLC1A3SLC1A2ALDH1A1MEN1
SCHEMBL5047137 0.84 PKM (0.62) PKMSLC1A3SLC1A2ALDH1A1MEN1
SCHEMBL5038056 0.84 PKM (0.53) PKMSLC1A3SLC1A2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 PKM 4225/4885SLC1A3 2652/4885SLC1A2 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.